CN113490512A - 组合药剂 - Google Patents

组合药剂 Download PDF

Info

Publication number
CN113490512A
CN113490512A CN202080017172.3A CN202080017172A CN113490512A CN 113490512 A CN113490512 A CN 113490512A CN 202080017172 A CN202080017172 A CN 202080017172A CN 113490512 A CN113490512 A CN 113490512A
Authority
CN
China
Prior art keywords
group
substituted
alkyl
salt
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080017172.3A
Other languages
English (en)
Chinese (zh)
Inventor
村尾英俊
小椋隼人
齐藤耕一
萩原真二
山浦刚
中谷俊幸
清井仁
石川裕一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of CN113490512A publication Critical patent/CN113490512A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080017172.3A 2019-02-28 2020-02-27 组合药剂 Pending CN113490512A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019035668 2019-02-28
JP2019-035668 2019-02-28
PCT/JP2020/008063 WO2020175629A1 (ja) 2019-02-28 2020-02-27 組合せ医薬

Publications (1)

Publication Number Publication Date
CN113490512A true CN113490512A (zh) 2021-10-08

Family

ID=72239685

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080017172.3A Pending CN113490512A (zh) 2019-02-28 2020-02-27 组合药剂

Country Status (8)

Country Link
US (1) US20210386768A1 (https=)
EP (1) EP3932429A4 (https=)
JP (1) JPWO2020175629A1 (https=)
CN (1) CN113490512A (https=)
AU (1) AU2020229558A1 (https=)
CA (1) CA3131852A1 (https=)
TW (1) TW202045174A (https=)
WO (1) WO2020175629A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202027749A (zh) * 2018-10-12 2020-08-01 日商富士軟片股份有限公司 急性骨髓性白血病用抗腫瘤劑
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
WO2023225005A1 (en) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor
WO2025012029A1 (en) * 2023-07-11 2025-01-16 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising 4-(4-methyl-piperazin-1-yl)-n-{6-[2-(4-trifluoromethyl-benzyloxy)-ethoxy]-1h-indazol-3-yl}-benzamide and an antineoplastic agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CN102438588B (zh) 2009-03-23 2015-04-01 埃姆比特生物科学公司 使用联合治疗法治疗疾病的方法
PT2840080T (pt) 2012-04-17 2018-02-06 Fujifilm Corp Composto heterocíclico que contém azoto ou sal do mesmo
CN105683167B (zh) 2013-10-16 2018-10-23 富士胶片株式会社 含氮杂环化合物的盐或其结晶、药品组合物及flt3抑制剂
WO2016027904A1 (ja) 2014-08-22 2016-02-25 富士フイルム株式会社 Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用
JP6412471B2 (ja) 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
TW202027749A (zh) * 2018-10-12 2020-08-01 日商富士軟片股份有限公司 急性骨髓性白血病用抗腫瘤劑

Also Published As

Publication number Publication date
WO2020175629A1 (ja) 2020-09-03
AU2020229558A1 (en) 2021-09-23
US20210386768A1 (en) 2021-12-16
EP3932429A4 (en) 2022-05-11
EP3932429A1 (en) 2022-01-05
JPWO2020175629A1 (https=) 2020-09-03
TW202045174A (zh) 2020-12-16
CA3131852A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
CN113490512A (zh) 组合药剂
JP6849711B2 (ja) Ｋｒａｓ ｇ１２ｃの共有結合性阻害剤
JP6736559B2 (ja) トリアゾロピリミジン化合物およびその使用
EP3423443B1 (en) Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
WO2025067459A2 (en) Therapies for the treatment of cancer
CN106068262B (zh) 喹唑啉衍生物及其制备方法和在医药上的应用
EP3472161B1 (en) Triazolopyridine compounds and uses thereof
EP3472166A1 (en) Imidazopyrimidine compounds useful for the treatment of cancer
US20210220355A1 (en) Antitumor agent for acute myeloid leukemia
JP7635237B2 (ja) ４－［［（７－アミノピラゾロ［１，５－ａ］ピリミジン－５－イル）アミノ］メチル］ピペリジン－３－オール化合物及びそれらの治療的使用
US20190225617A1 (en) Ripk2 inhibitors and method of treating cancer with same
AU2015402778A2 (en) Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
CN116113406B (zh) Gas41抑制剂及其使用方法
BR112021010645A2 (pt) composto, 1-(((s)-7-((r)-3-ciclohexil-2-metilpropanoil)-10-hidroxi-7-azaspiro[4.5]decan-10-il)metil)-4-fenil-5-(piperazina-1-carbonila)piridin-2(1h)-ona, composição farmacêutica, métodos para tratamento de obesidade, de resistência à insulina, de diabetes tipo ii, de atrofia muscular, de câncer e para reduzir perda de massa muscular, e, inibidor de usp19
CN1889952A (zh) (a)N－{5－[4－(4－甲基－(哌嗪－1－基)－甲基)－苯甲酰胺基]－2－甲基苯基}－4－(3－吡啶基)－2－嘧啶－胺和( b )至少一种羟丁赖氨酸形成抑制剂的组合产品及其用途
HK40057625A (en) Combinational medication
US20240360135A1 (en) Imidazo[1,2-b]pyridazinyl compounds and uses thereof
WO2020198067A1 (en) Pkm2 modulators and methods for their use
JP2009504674A (ja) 有機化合物の組合せ
HK40046231A (en) Antitumor agent for acute myeloid leukemia
CN103848833B (zh) 吡咯并三嗪类衍生物、其制备方法及其在医药上的应用
JP2024544019A (ja) 化合物
JP2024502130A (ja) チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤の形態及び製剤
TW201406751A (zh) 取代的吡唑酮化合物及其使用方法
HK1239664B (en) Triazolopyrimidine compounds and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40057625

Country of ref document: HK